Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 243-250

  Chung, J ^a   Brass, E P ^b   Ulrich, R G ^c   Hiatt, W R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c ROSETTA INPHARMATICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; BICYCLE ERGOMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENERGY EXPENDITURE; EXERCISE; EXERCISE TEST; FATTY ACID OXIDATION; FEMALE; HUMAN; HYPERTENSION; LUNG GAS EXCHANGE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; SKELETAL MUSCLE;

ADULT; ANAEROBIC THRESHOLD; CHOLESTEROL, LDL; CREATINE KINASE; DOUBLE-BLIND METHOD; ENERGY METABOLISM; EXERCISE; FATTY ACIDS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PULMONARY GAS EXCHANGE; PULMONARY VENTILATION; PYRROLES; REFERENCE VALUES; TIME FACTORS;

EID: 38349115469     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100264     Document Type: Article

References (37)

1. MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
2. LaRosa, J.C. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
4. Jamal, S.M., Eisenberg, M.J. & Christopoulos, S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. Heart J. 147, 956-965 (2004).
5. Thompson, P.D., Clarkson, P. & Karas, R.H. Statin-associated myopathy. JAMA 289, 1681-1690 (2003).
6. Paiva, H. et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin. Pharmacol. Ther. 78, 60-68 (2005).
7. Phillips, P.S., Phillips, C.T., Sullivan, M.J., Naviaux, R.K. & Haas, R.H. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 177, 183-188 (2004).
8. Laaksonen, R. et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 1, e97 (2006).
9. Kaufmann, P., Torok, M., Zahno, A., Waldhauser, K.M., Brecht, K. & Krahenbuhl, S. Toxicity of statins on rat skeletal muscle mitochondria. Cell. Mol. Life Sci. 63, 2415-2425 (2006).
10. Sirvent, P. et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem. Biophys. Res. Commun. 338, 1426-1434 (2005).
11. Phillips, P.S. et al. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137, 581-585 (2002).
12. 2+ signaling alteration in skeletal muscle. Biochem. Biophys. Res. Commun. 329, 1067-1075 (2005).
13. Paolisso, G. et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150, 121-127 (2000).
14. Poole, D.C. & Richardson, R.S. Determinants of oxygen uptake. Implications for exercise testing. Sports Med. 24, 308-320 (1997).
15. DuBois, E.F. A graphic representation of the respiratory quotient and the percentage of calories from protein, fat and carbohydrate. J. Biol. Chem. 59, 43-49 (1924).
16. Bergman, B.C., Butterfield, G.E., Wolfel, E.E., Casazza, G.A., Lopaschuk, G.D. & Brooks, G.A. Evaluation of exercise and training on muscle lipid metabolism. Am. J. Physiol. 276(Part 1): E106-E117 (1999).
17. Blomstrand, E., Radegran, G. & Saltin, B. Maximum rate of oxygen uptake by human skeletal muscle in relation to maximal activities of enzymes in the Krebs cycle. J. Physiol. 501(Part 2): 455-460 (1997).
18. Huptas, S., Geiss, H.C., Otto, C. & Parhofer, K.G. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am. J. Cardiol. 98, 66-69 (2006).
19. Costa, A. et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet. Med. 20, 743-745 (2003).
20. Kishi, T., Hirooka, Y., Mukai, Y., Shimokawa, H. & Takeshita, A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J. Hypertens. 21, 379-386 (2003).
21. Tsivgoulis, G., Spengos, K., Karandreas, N., Panas, M., Kladi, A. & Manta, P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch. Intern. Med. 166, 1519-1524 (2006).
22. Vladutiu, G.D. et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34, 153-162 (2006).
23. Rasmussen, U.F., Rasmussen, H.N., Krustrup, P., Quistorff, B., Saltin, B. & Bangsbo, J. Aerobic metabolism of human quadriceps muscle: in vivo data parallel measurements on isolated mitochondria. Am. J. Physiol. Endocrinol. Metab. 280, E301-E307 (2001).
24. Wang, H., Hiatt, W.R., Barstow, T.J. & Brass, E.P. Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. Eur. J. Appl. Physiol. 80, 22-27 (1999).
25. Rasmussen, U.F. & Rasmussen, H.N. Human skeletal muscle mitochondrial capacity. Acta Physiol. Scand. 168, 473-480 (2000).
26. Morikawa, S. et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J. Atheroscler. Thromb. 11, 62-72 (2004).
27. Morikawa, S. et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J. Atheroscler. Thromb. 12, 121-131 (2005).
28. Urso, M.L., Clarkson, P.M., Hittel, D., Hoffman, E.P. & Thompson, P.D. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler. Thromb. Vasc. Biol. 25, 2560-2566 (2005).
29. 2 uptake relationship during incremental exercise in man. Exp. Physiol. 77, 51-64 (1992).
30. Jequier, E., Acheson, K. & Schutz, Y. Assessment of energy expenditure and fuel utilization in man. Annu. Rev. Nutr. 7, 187-208 (1987).
31. Beaver, W.L., Wasserman, K. & Whipp, B.J. A new method for detecting anaerobic threshold by gas exchange. J. Appl. Physiol. 60, 2020-2027 (1986).
32. Allain, C.C., Poon, L.S., Chan, C.S., Richmond, W. & Fu, P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 20, 470-475 (1974).
33. Demacker, P.N., Hijmans, A.G. & Jansen, A.P. Enzymic and chemical-extraction determinations of free fatty acids in serum compared. Clin. Chem. 28, 1765-1768 (1982).
34. Marbach, E.P. & Weil, M.H. Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant. Clin. Chem. 13, 314-325 (1967).
35. Bucolo, G. & David, H. Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem. 19, 476-482 (1973).
36. Mazzeo, R.S., Child, A., Butterfield, G.E., Mawson, J.T., Zamudio, S. & Moore, L.G. Catecholamine response during 12 days of high-altitude exposure (4,300 m) in women. J. Appl. Physiol. 84, 1151-1157 (1998).
37. Morgan, C.R. & Lazarow, A. Immunoassay of insulin using a two-antibody system. Proc. Soc. Exp. Biol. Med. 110, 29-32 (1962).